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Abstract
Background: Previous work from this laboratory has shown that the administration of the
convulsant drug 3-mercaptopropionic acid (MP), a GAD inhibitor, modifies not only GABA
synthesis but also binding of the antagonist [3H]-quinuclidinyl benzilate ([3H]-QNB) to central
muscarinic receptors, an effect due to an increase in affinity without modifications in binding site
number. The cholinergic system has been implicated in several experimental epilepsy models and
the ability of acetylcholine to regulate neuronal excitability in the neocortex is well known. To
study the potential relationship between GABAergic and cholinergic systems with seizure activity,
we analyzed the muscarinic receptor after inducing seizure by bicuculline (BIC), known to
antagonize the GABA-A postsynaptic receptor subtype.
Results: We analyzed binding of muscarinic antagonist [3H]-QNB to rat CNS membranes after i.p.
administration of BIC at subconvulsant (1.0 mg/kg) and convulsant (7.5 mg/kg) doses. Subconvulsant
BIC dose failed to develop seizures but produced binding alteration in the cerebellum and
hippocampus with roughly 40% increase and 10% decrease, respectively. After convulsant BIC
dose, which invariably led to generalized tonic-clonic seizures, binding increased 36% and 15% to
cerebellar and striatal membranes respectively, but decreased 12% to hippocampal membranes. Kd
value was accordingly modified: with the subconvulsant dose it decreased 27% in cerebellum
whereas it increased 61% in hippocampus; with the convulsant dose, Kd value decreased 33% in
cerebellum but increased 85% in hippocampus. No change in receptor number site was found, and
Hill number was invariably close to unity.
Conclusion: Results indicate dissimilar central nervous system area susceptibility of muscarinic
receptor to BIC. Ligand binding was modified not only by a convulsant BIC dose but also by a
subconvulsant dose, indicating that changes are not attributable to the seizure process itself.
Findings support the notion that the muscarinic receptors play a major role in experimental
epilepsy and provide a new example of differential neuronal plasticity.
Background
An imbalance between inhibition and excitation in the
CNS may lead to seizures that involve the synchronous
and repetitive discharges of a large group of neurons.
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Convulsant drug administration has proven to be effective
and therefore a useful tool to study experimental epilepsy,
since it produces behavioral modifications concomitant
with marked neurochemical changes. Acetylcholine is an
essential neurotransmitter/neuromodulator in several
experimental epilepsy disorders [1], and its ability to reg-
ulate neuronal excitability in neocortex is well known [2].
Interestingly, the anticonvulsant effect mediated by carba-
chol microinjection in the nucleus reticularis pontis oralis
appears to be mediated by muscarinic receptors [3].
GABA is the major central inhibitory neurotransmitter,
and it is not surprising, therefore, that it has been involved
in epileptic activity genesis [4-6]. The biosynthesis of
GABA requires the activity of glutamic acid decarboxylase
(GAD), a cytosolic enzyme that is found in neurons where
GABA is a neurotransmitter.
Previous work from this laboratory has shown that the
administration of the convulsant drug 3-mercaptopropi-
onic acid (MP), a GAD inhibitor [7], modifies not only
GABA synthesis [8,9] but also binding of antagonist [3H]-
quinuclidinyl benzilate ([3H]-QNB) to central muscarinic
receptors, an effect due to an increase in affinity without
modifications in binding site number [10-12].
To study potential relationship between GABAergic and
cholinergic systems with seizure activity, we analyzed the
muscarinic receptor after inducing seizure by bicuculline
(BIC), known to antagonize GABA-A postsynaptic recep-
tor subtype [13]. Subconvulsant and convulsant BIC
doses were administered to rats and [3H]-QNB binding to
cortical, striatal, cerebellar and hippocampal membranes
assayed. As significant changes were found in cerebellum
and hippocampus (increase and decrease, respectively),
such membranes were chosen to perform saturation stud-
ies and Scatchard analysis, to observe significant altera-
tion in binding affinitty.
Results
Kinetic studies in experiments of association-dissociation
binding for [3H]-QNB were performed in control rat cere-
bral cortex membranes. The time course was analyzed
between 1 and 180 min at 30°C (Fig. 1). Binding param-
eters obtained (mean values ± S. D., n = 3) were: kobs (min-
1) = 0.08 ± 0.02; kon (min-1 .nM-1) = 0.8 ± 0.2; koff = 0.03 ±
0.004; Kd = koff/kon (nM) = 0.04 and Kd' (nM) = 0.136 ±
0.050. The discrepancy in the values of the Kd' and the Kd
obtained in the equilibrium and kinetic experiments,
respectively, is probably a consequence of the high recep-
tor concentration used in the binding assays [14]. Since
binding equilibrium was attained at 40 – 50 min, further
experiments were carried out at 60 min incubation.
To examine potential changes in muscarinic receptors,
[3H]-QNB binding to rat CNS membranes isolated from
control and BIC treated animals was assayed.
Effect of a subconvulsant BIC dose
Intraperitoneal rat administration of 1.0 mg/kg BIC failed
to develop seizures but slight abnormal behaviour
changes as sniffing and intensive washing movements
were observed during 5–10 minutes, when animals recov-
ered normal behavior.
Significant changes in [3H]-QNB binding in cerebellum
and hippocampus were found. In cerebellum, an increase
of roughly 40% was recorded, since ligand binding in
pmol per mg protein was 0.50 in BIC treated versus 0.35 in
control group. In hippocampus, 10% decrease was
obtained, with values of 1.35 in BIC treated versus 1.50 in
control group. No significant changes were found in cor-
tical or striatal membranes (Table 1).
Effect of a convulsant BIC dose
Intraperitoneal rat injection of 7.5 mg/kg BIC resulted in
the development of generalized tonic-clonic seizures. As a
rule, after 90–120 sec latency, rats suddenly ran amok
(during 10–30 sec), then became motionless, regained
tonus (30–45 sec), and ended up with a four-limb clonic
phase (90–150 sec). Present experiments were performed
with animals decapitated at the onset of seizure, during
the running stage.
At seizure stage, [3H]-QNB binding to cerebellar mem-
branes exhibited 36% increase, since ligand binding in
pmol per mg protein was 0.46 in BIC treated versus 0.34 in
control group. Again, a 12% decrease was observed in hip-
pocampus, with data, in pmol per mg protein, of 1.36 in
BIC versus 1.50 in control group. [3H]-QNB binding to
striatal membranes increased 15% with values of 2.27 in
BIC treated versus 1.98 in control group; no significant
changes were found in cortical membranes (Table 2).
Saturation studies
In order to determine whether binding changes observed
in cerebellum and hippocampus were due to modifica-
tions in affinity and/or site number, [3H]-QNB binding
was studied at variable ligand concentrations. Saturation
values were attained with 0.50–1.00 nM ligand in mem-
branes after subconvulsant and convulsant BIC doses as
well as in control membranes (Figs. 2, 3, 4, 5).
Scatchard analysis of [3H]-QNB binding data recorded at
equilibrium disclosed a significant decrease (27%) in cer-
ebellum Kd value in membranes obtained from rats
treated with 1.0 mg/kg BIC dose; on the contrary, hippoc-
ampus Kd value increased 61%. No change in receptor site
number was recorded in either area. Hill number wasBMC Neuroscience 2006, 7:32 http://www.biomedcentral.com/1471-2202/7/32
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close to unity and remained unaltered in both cerebellar
and hippocampal membranes (Table 3).
At seizure stage, Kd value decreased 33% in cerebellum,
but increased 85% in hippocampus. No significant
change in Bmax was found either in cerebellar or hippoc-
ampal membranes. Here again, Hill number was close to
unity and remained unaltered in either case (Table 4).
Equilibrium binding data for [3H]-QNB recorded at sev-
eral ligand concentrations were analyzed by a computer to
disclose whether a single or two population sites were
operative; it was observed that the best fit indicated a sin-
gle population site.
Discussion
To analyze muscarinic receptor under GABA-A receptor
blockade, [3H]-QNB binding to rat CNS membranes after
the administration of subconvulsant and convulsant BIC
doses was studied. The subconvulsant BIC dose produced
significant changes in [3H]-QNB binding, with an increase
in cerebellar but a decrease in hippocampal membranes,
without alterations in either striatal or cortical mem-
branes. With the convulsant BIC dose, binding increased
to cerebellar and striatal membranes but decreased to hip-
pocampal membranes whereas it remained unaltered to
cortical membranes. Whenever alterations in binding
were recorded, they were invariably due to affinity
changes alone, since site number remained constant.
Scatchard plots obtained at equilibrium rendered linear
profiles and Hill number was close to unity, suggesting
that [3H]-QNB binds to a homogeneous site population
in all cases.
On the basis of studies performed in diverse animal mod-
els, the concept that epileptic episodes may be caused by
imbalance between inhibition and excitation inputs has
been advanced [1,15-17]. Synaptic inhibition is a regula-
tory and crucial mechanism which limits the generation
of action potential in neurons.
Glutamatergic NMDA receptors are known to exert a role
in seizure [18,19]; however, the possible involvement of
other receptor types, i. e., muscarinic receptors, has been
advanced [4,20-22], among which M1 is the only subtype
mediating pilocarpine-induced seizure [23,24].
Several lines of evidence point to a relationship between
cholinergic muscarinic activation, GABA system and sei-
zure activity. Previous work from this laboratory has
shown that convulsant MP modifies GABA system by
decreasing GAD activity and GABA levels as well as alter-
ating of cerebellar Purkinje cell morphology [8,9]. With a
convulsant MP dose, [3H]-QNB binding to muscarinic
receptors is enhanced in CNS, an effect due to an increase
in affinity without changes in binding site number
[10,11]. However, a subconvulsant MP dose fails to
induce any change [10-12]. Herein it is shown that BIC
Table 1: Effect of a subconvulsant BIC dose (1.0 mg/kg, i.p.) on [3H]-QNB binding to membranes isolated from four brain areas.
Area [3H]-QNB binding
Condition
Control pmol.mg protein-1 Subconvulsive pmol.mg protein-1 ∆ (%)
Cerebellum 0.35 ± 0.04 (3) 0.50 ± 0.04** (3) + 43
Hippocampus 1.50 ± 0.03 (3) 1.35 ± 0.03* (3) - 10
Striatum 1.98 ± 0.11 (3) 2.09 ± 0.05 (3) + 6
Cerebral cortex 1.35 ± 0.04 (3) 1.44 ± 0.14 (3) + 7
Values are means ± S.D. Figures in parentheses denote number of separate experiments performed in triplicate.
* P < 0.05, ** P < 0.01 (Student's-t test).
Table 2: Effect of a convulsant BIC dose (7.5 mg/kg, i.p.) on [3H]-QNB binding to membranes isolated from brain areas.
Area [3H]-QNB binding
Condition
Control pmol.mg protein-1 Convulsive pmol.mg protein-1 ∆ (%)
Cerebellum 0.34 ± 0.03 (6) 0.46 ± 0.03*** (6) + 36
Hippocampus 1.55 ± 0.07 (6) 1.36 ± 0.08** (6) - 12
Striatum 1.98 ± 0.11 (3) 2.27 ± 0.14* (3) + 15
Cerebral cortex 1.35 ± 0.04 (3) 1.42 ± 0.04 (3) + 5
Values are means ± S.D. Figures in parentheses denote number of separate experiments performed in triplicate.
* P < 0.05, ** P < 0.01, *** P < 0.001 (Student's-t test).BMC Neuroscience 2006, 7:32 http://www.biomedcentral.com/1471-2202/7/32
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administration either at subconvulsant or convulsant
dose, is able to modify [3H]-QNB binding to muscarinic
receptor. Therefore, the explanation that alteration of
muscarinic receptor is a consequence of seizure process
seems untenable.
The increase in ligand binding to striatal and cerebellar
membranes with convulsant BIC dose may well indicate
the activation of cholinergic excitatory circuits. These find-
ings are consistent with the observation that muscarinic
receptor activation during BIC blockade of GABA-A-medi-
ated potentials induces synchronous epileptiform activity
in immature rat CNS [25,26].
Herein we recorded a small but significant decrease in
binding in hippocampal membranes obtained with con-
vulsant and subconvulsant BIC doses, an expected result
since after short seizure hippocampus undergoes cellular,
functional and structural alterations following the admin-
istration of convulsant drugs [27-29]. Interestingly, in this
epileptogenic area, interactions between cholinergic and
GABAergic systems have been doccumented [16,30-32].
Present results in hippocampus differ from those recorded
with convulsant MP [10-12], a finding which may receive
an explanation in the different mechanism of action of
BIC versus MP.
As regards results recorded in striatum, where binding
changes were observed only after BIC convulsant dose, it
should be recalled that this area participates in motor
activities. In this connection, muscarinic receptor altera-
Table 3: [3H]-QNB binding constants in cerebellar and hippocampal membranes after administration of a subconvulsant BIC dose (1.0 
mg/kg).
Area Condition Kd (pM) ∆ (%) Bmax (pmol.mg prot-1)N H
Cerebellum Control 197.5 ± 6.0 0.36 ± 0.08 1.01 ± 0.02
Subconvulsive 144.9 ± 5.5*** - 27 0.42 ± 0.07 0.98 ± 0.03
Hippocampus Control 115.4 ± 5.8 2.31 ± 0.09 0.97 ± 0.04
Subconvulsive 185.6 ± 3.9*** + 61 2.38 ± 0.10 0.96 ± 0.02
For each experiment, cerebellum and hippocampus from five rats were pooled, membranes separated and [3H]-QNB binding assayed. Data from 
three experiments were processed to calculate constants. Results presented are mean values ± S.D.
*** P < 0.001 (Student's-t test).
Scatchard plots for [3H]-QNB binding to rat cerebellar mem- branes at equilibrium after administration of a subconvulsant  BIC dose (1.0 mg/kg) Figure 2
Scatchard plots for [3H]-QNB binding to rat cerebellar mem-
branes at equilibrium after administration of a subconvulsant 
BIC dose (1.0 mg/kg). Results are from a single experiment 
representative of a set of three, each performed in duplicate. 
Inset, saturation curves. (● ) Control; (▲ ) BIC subconvulsive.
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Dissociation kinetic for [3H]-QNB binding to rat control cer- ebral cortex membranes Figure 1
Dissociation kinetic for [3H]-QNB binding to rat control cer-
ebral cortex membranes. Assay was performed at 30°C with 
0.5 nM [3H]-QNB. At different time intervals (1 to 180 min), 
3 ml samples were filtered and washed. Values represent a 
single experiment performed in duplicate.
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tion in striatum is observed after high doses of muscarinic
agonist pilocarpine [33].
Among CNS studied areas, cerebellum presents the lowest
density of muscarinic receptor sites; however, the greatest
changes in [3H]-QNB binding after BIC administration
were recorded in this area, attributable to cerebellum par-
ticipation in motor activity, markedly altered during con-
vulsive activity.
Normal neurophysiological functions as adaptation, inhi-
bition and facilitation, among others, are associated with
plasticity, participating in compensatory processes by
which the CNS adapts to pathological conditions, expo-
sure to drugs and neuronal damage and loss [34]. Neuro-
nal plasticity evidences the response of a circuit, a
neurotransmitter or a receptor that is modified as a result
of different factors or altered processes. Herein it is shown
that muscarinic receptor changed promptly after stimulus
(BIC administration), a finding in line with the observa-
tion that this receptor is enhanced in the human epileptic
focus at early times following seizures through activity-
dependent mechanisms [35].
On comparing previous results obtained with MP versus
present findings with BIC, a differential response of mus-
carinic receptor is evident according to GABA system site
alteration, that is, when GAD activity is inhibited or
GABA-A receptor antagonized.
Table 4: [3H]-QNB binding constants in cerebellar and hippocampal membranes after administration of a convulsant (7.5 mg/kg) BIC 
dose.
Area Condition Kd (pM) ∆ (%) Bmax (pmol.mg prot-1)N H
Cerebellum Control 200.1 ± 7.1 0.35 ± 0.01 1.00 ± 0.01
Convulsive 133.3 ± 7.5*** - 33 0.42 ± 0.07 1.05 ± 0.02
Hippocampus Control 108.8 ± 2.7 1.75 ± 0.08 1.01 ± 0.06
Convulsive 185.6 ± 3.9*** + 85 1.72 ± 0.11 0.98 ± 0.02
For each experiment, cerebellum and hippocampus from five rats were pooled, membranes separated and [3H]-QNB binding assayed. Data from 
three experiments were processed to calculate constants. Results presented are mean values ± S.D.
*** P < 0.001 (Student-t test).
Scatchard plots for [3H]-QNB binding to rat cerebellar mem- branes at equilibrium after administration of a convulsant BIC  dose (7.5 mg/kg) Figure 4
Scatchard plots for [3H]-QNB binding to rat cerebellar mem-
branes at equilibrium after administration of a convulsant BIC 
dose (7.5 mg/kg). Results are from a single experiment repre-
sentative of a set of three, each performed in duplicate. Inset, 
saturation curves. (● ) Control; (▲ ) BIC seizure.
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Scatchard plots for [3H]-QNB binding to rat hippocampal  membranes at equilibrium after administration of a subcon- vulsant BIC dose (1.0 mg/kg) Figure 3
Scatchard plots for [3H]-QNB binding to rat hippocampal 
membranes at equilibrium after administration of a subcon-
vulsant BIC dose (1.0 mg/kg). Results are from a single exper-
iment representative of a set of three, each performed in 
duplicate. Inset, saturation curves. (● ) Control; (▲ ) BIC sub-
convulsive.
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To sum up, results indicate that: 1) seizure activity itself is
not the sole mechanism liable to produce a change in
muscarinic receptors, since a subconvulsant BIC dose also
induces modifications; 2) there is dissimilar area suscepti-
bility for muscarinic receptor to BIC; and 3) muscarinic
receptor response to convulsant drugs (MP or BIC) sup-
port differential neuronal plasticity. Findings support the
notion that muscarinic receptors play a major role in
experimental epilepsy,
Conclusion
Results indicate dissimilar central nervous system area
susceptibility of muscarinic receptor to BIC. Ligand bind-
ing was modified not only by a convulsant BIC dose but
also by a subconvulsant dose, indicating that changes are
not attributable to seizure process itself. Findings support
the notion that the muscarinic receptors play a major role
in experimental epilepsy and provide a new example of
differential neuronal plasticity.
Methods
Animals and drug treatment
Young adult male Wistar rats (25 days old) weighing 100–
150 g were used. Animals caged in groups of five were
housed at constant temperature (20–23°C) and main-
tained at least one week in a 12 h light-dark cycle (from
9.00 a.m. to 9.00 p.m.) with free access to food and water.
Rats were injected i.p. between 9.30 and 11.30 a.m. with
fresh BIC solutions to reach 1.0 and 7.5 mg/kg doses. BIC
(Sigma, St. Louis, MO) was dissolved in 0.1 N HCl,
brought to pH 5 with 0.1 N NaOH and immediately
injected. All studies described were conducted in accord-
ance with the Guide for Care and Use of Laboratory Ani-
mals provided by the National Institutes of Health, USA.
Experimental groups
Three experimental groups were used: control, subconvul-
sant, and convulsant. Animals in the control group
received no treatment. In the subconvulsant group, rats
were injected with 1 mg/kg BIC dose, a dose which failed
to induce seizure or behavioral modifications. In the con-
vulsant group, animals were injected with 7.5 mg/kg BIC,
a dose that produced generalized tonic-clonic seizures.
For each BIC dose, lots of 5 rats each time with their cor-
responding controls were used.
Rats were decapitated at 30 min after injection (subcon-
vulsant stage or condition) or at the onset of seizure (con-
vulsant stage or condition), respectively. Each condition
was repeated 3–6 times.
Since saline administration produces no change in any of
the areas studied [11], uninjected rats were used as con-
trols.
Membrane preparations
For each experimental condition cerebellum, hippocam-
pus, cerebral cortex and striatum from five animals were
harvested and separately pooled. Tissues were rapidly
homogenized at 10% w/v, except for cerebral cortex at 4%
w/v, in 0.32 M sucrose neutralized with Tris base solution
(0.4 mM Tris final concentration) in a Teflon glass Potter-
Elvehjem homogenizer.
Homogenates were centrifuged at 900 g for 10 min and
pellets discarded; resulting supernatants were diluted with
0.16 M sucrose to achieve a final concentration of 0.25 M
sucrose, centrifuged at 100,000 g for 30 min and mem-
brane pellets stored at -70°C until use.
[3H]-QNB binding assay
[3H]-QNB binding was determined according to the
method described by Yamamura and Snyder [36] with
slight modifications. Membrane pellets were resuspended
and later diluted in 50 mM sodium, potassium phosphate
buffer (pH 7.4) to reach 0.1 mg protein/ml concentration.
Triplicate membrane aliquots were incubated (2 ml final
volume) at 30°C in the presence of 0.5 nM L- [3H]-QNB
(S- [3H]-QNB enantiomer), Du Pont Corp. New England
Nuclear, Boston, MA, USA, specific activity 14,443 GBq/
mmol), with or without 5 µM atropine sulfate. Incubation
proceeded for 60 min, because [3H]-QNB binding reached
Scatchard plots for [3H]-QNB binding to rat hippocampal  membranes at equilibrium after administration of a convul- sant BIC dose (7.5 mg/kg) Figure 5
Scatchard plots for [3H]-QNB binding to rat hippocampal 
membranes at equilibrium after administration of a convul-
sant BIC dose (7.5 mg/kg). Results are from a single experi-
ment representative of a set of three, each performed in 
duplicate. Inset, saturation curves. (● ) Control; (▲ ) BIC sei-
zure.
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equilibrium after 45 min incubation, in agreement with
data from the literature [37-39].
After incubation, 3 ml of ice-cold sodium, potassium
phosphate buffer were added and samples vacuum-fil-
tered through Whatman GF/B glass disks. Filters were
washed twice with 3 ml of ice-cold buffer, placed in plastic
vials and dried overnight at 70°C. To each vial, 3 ml of
0.4% 2,5-diphenyl-oxazole in toluene were added and
radioactivity quantified in a liquid scintillation counter.
Specific binding was calculated as the difference between
the binding in the absence and presence of 5 µM atropine
sulfate, and represented ca 90% of total binding.
Results averaged were obtained with different membranes
isolated from tissue pooled (from 5 rats each group). The
whole experiment (BIC administration, tissue harvesting,
membrane preparation and binding assay in triplicate)
was carried out in 3 or 6 different occasions.
For saturation studies, duplicate membrane samples were
incubated in the presence of [3H]-QNB ranging from
0.125 to 2.00 nM concentration and processed as
described above. The same basic filtration assay was used
in experiments in which the kinetics of binding were
investigated. For measurement of association rates, cere-
bral cortex membranes were incubated at 0.1 mg/ml pro-
tein concentration, in the presence of 0.5 nM L- [3H]-
QNB. At different time intervals extending over 180 min,
3 ml samples were removed and filtered as indicated
above. Additional samples were incubated in the presence
of 5 µM atropine sulfate to assay nonspecific binding. The
measurement of dissociation rates was performed in a
similar way on membranes that had reached equilibrium
binding after incubation for 60 min in the presence of 0.5
nM L- [3H]-QNB.
Protein was assayed according to Lowry et al. [40] using
bovine serum albumin as standard.
Data analysis
Differences in mean values between groups were evalu-
ated by Student's-t  test. Significance levels were set at
P<0.05.
For saturation assays, non-linear regression of the data
were processed using EBDA program (G. A. Mc Pherson
1983 V 2.0). Scatchard transformation of the data
obtained at equilibrium was employed to show whether
more than one receptor population was operative.
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